Provention Bio
United States
188 articles about Provention Bio
-
Provention Bio entered a co-promotion agreement with Sanofi ahead of the possible November approval of teplizumab. If approved, the drug would be the first approved to modify T1D.
-
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
10/6/2022
Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022.
-
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
10/6/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention's lead investigational drug candidate teplizumab.
-
Provention Bio Announces Senior Leadership Addition
9/19/2022
Provention Bio, Inc. today announced that the Company has appointed Sarah O'Brien as Chief People Officer.
-
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.
-
Provention Bio Announces the Grant of Inducement Awards - Sep 02, 2022
9/2/2022
Provention Bio, Inc. announced that the Company granted stock options to two non-executive employees to purchase an aggregate of 38,000 shares of common stock.
-
Provention Bio secured a $125 million loan from Hercules Capital that will support operations and the potential launch of the company's type 1 diabetes treatment, teplizumab.
-
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
8/31/2022
Provention Bio, Inc. announced that the Company has secured a term loan facility of up to $125 million with Hercules Capital, Inc., a leader in customized financing for companies in life sciences.
-
This week holds moments of truth for Provention's type 1 diabetes drug and bluebird bio's gene therapy for beta-thalassemia. Amicus and Incyte are coming up at the end of the month.
-
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the second quarter ended June 30, 2022, and provided a business update.
-
Provention Bio Announces the Grant of Inducement Awards - Aug 02, 2022
8/2/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to nine non-executive employees to purchase an aggregate of 118,000 shares of common stock.
-
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 , before the opening of the U.S. financial markets.
-
Provention Bio Announces $60 Million Private Placement
7/8/2022
Provention Bio, Inc. announced it has entered into a securities purchase agreement with institutional investors for the private placement of approximately $60 million of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock .
-
Provention Bio Announces the Grant of Inducement Awards - July 05, 2022
7/5/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 7,000 shares of common stock.
-
Provention Bio announced the FDA extended its review period by three months for the Biologics License Application (BLA) of its diabetes prevention drug, teplizumab to Nov. 17.
-
Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
6/30/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended its review period by three months for the Biologics License Application (BLA) for teplizumab.
-
Provention Bio to Present at the Jefferies Global Healthcare Conference
6/3/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8th 2022 at 9:00 am EST in New York City.
-
Provention Bio Announces the Grant of Inducement Awards - June 03, 2022
6/3/2022
Provention Bio, Inc. announced that the Company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock.
-
Provention Bio Announces Update to Board of Directors
6/3/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on the Company's board of directors to focus on his other commitments, including his role as President and Chief Executive Officer.
-
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
5/12/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on Thursday, May 19, 2022 focused on the potential commercial launch of teplizumab in the second half of this year.